SPEAKERS

Antibacterial Drug Development Speakers:

John Domagala, Ph.D., Senior Director, Research, International Discovery Sourcing Consultants, LLC
Thomas D. Gootz, Ph.D., Thomas Gootz Consulting
Roger B. Clark, Ph.D., Director of Medicinal Chemistry, Tetraphase Pharmaceuticals, Inc.
Eric Burak, Ph.D., Vice President, Preclinical and Early Clinical Development, Rib-X Pharmaceuticals, Inc.
Andrea Marra, Ph.D., Associate Director, Preclinical Development, Rib-X Pharmaceuticals, Inc.
Herbert Schweizer, Ph.D., Professor, Microbiology, Immunology and Pathology, Colorado State University
Graham Timmins, Ph.D., Associate Professor, Medicinal Chemistry,College of Pharmacy, University of New Mexico
Zoltan Kanyo, Ph.D., Scientist, Structure-Based Drug Design, Rib-X Pharmaceuticals, Inc.
Vincent Hernandez, Senior Scientist, Medicinal Chemistry, Anacor Pharmaceuticals
Klaus Dembowsky, M.D., Ph.D., Head, Protein Epitope Mimetics; Medical Director, Polyphor Ltd.
Malcolm Page, Professor; Head of Biology, Research, Basilea Pharmaceutica International
Joseph Blondeau, Ph.D., Head, Clinical Microbiology, Royal University Hospital and University of Saskatchewan
Dmitri Debabov, Ph.D., Assistant Director, Micro and Cell Biology, NovaBay Pharmaceuticals
Stefan Miller, Ph.D., CEO, Lisando GmbH
Helen I. Zgurskaya, Ph.D., Associate Professor of Chemistry and Biochemistry, University of Oklahoma

Fragment-Based Drug Discovery Speakers:

Maurizio Pellecchia, Ph.D., Professor, Burnham Institute for Medical Research
Antonio Pineda-Lucena, Ph.D., Principal Investigator, Structural Biology, Medicinal Chemistry, Centro de Investigación Príncipe Felipe
Sandy Farmer, Ph.D., Director, Structural Research, Boehringer Ingelheim Pharmaceuticals, Inc.
Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group
Girija Krishnamurthy, Ph.D., Principal Research Scientist, Pfizer, Inc.
Shikha Varma-O’Brien, Ph.D., Director, Life Sciences Modeling & Simulations, Accelrys, Inc.
Peter Brandt, Ph.D., CSO, Beactica
Roderick E. Hubbard, Ph.D., Professor, Research, Vernalis, Ltd.
Cathy Moore, Ph.D., formerly Senior Principal Scientist, Pfizer, Inc.
Andrew Woodhead, Ph.D., Associate Director, Medicinal Chemistry, Astex Therapeutics
Doug Davies, Senior Director, Emerald BioStuctures
Daniel Obrecht, Ph.D., CSO, Polyphor Ltd.
Gerhard Mueller, Ph.D., CSO, Drug Discovery, Proteros fragments
Noeris Salam, Ph.D., Applications Scientist, Schrödinger, LLC
Daniel Wyss, Ph.D., Chemical Research Fellow, NMR,Schering-Plough
Joerg Scheuermann, Ph.D., Senior Scientist, Chemistry and Applied Biosciences, ETH Zurich

Anti-Inflammatories: Small Molecule Approaches Speakers:

Mark Flanagan, Ph.D., Senior Principal Scientist, World Wide Medicinal Chemistry, Pfizer, Inc.
Jonathan Fridman, Ph.D., Director, Pharmacology, Incyte
William Pitts, Ph.D., Group Leader, Medicinal Chemistry, Bristol-Myers Squibb
Juswinder Singh, Ph.D., CSO, Avila Therapeutics
Wei Chen, Ph.D., Scientist IIIt, Medicinal Chemistry, Pharmacyclics
Yousef Al-Abed, Ph.D., Professor and Director, Department of Medicinal Chemistry, Feinstein Institute
John Wallace, Ph.D., CSO, Antibe Therapeutics
Jeffrey Whitten, Ph.D., Vice President, Chemistry, CalciMedica, Inc.
Allan SY Lau, M.D., Professor, Cytokine Biology Group and BioScreening Unit, Li Ka Shing Faculty of Medicine, University of Hong Kong
Paul Davis, M.D., Director, Signal Transduction, Ordway Research Institute; Professor of Medicine, Albany Medical College; Professor of Pharmacy, Albany College of Pharmacy and Health Sciences
Jennifer Venable, Ph.D., Senior Scientist, Immunology Chemistry, Johnson & Johnson PRD
Vidal de la Cruz, Ph.D., Vice President, Cytokine PharmaSciences, Inc.
Daniel Flynn, Ph.D., President and CEO, Research & Development, Deciphera Pharmaceuticals

HCV Drug Discovery Speakers:

Youssef Bennani, Ph.D., Vice President Drug Innovation, Research Management, Vertex Pharmaceuticals
Francisco Talamas, Ph.D., Associate Director, Virology, Roche Palo Alto
Michael J. Sofia, Ph.D., Vice President, Chemistry, Pharmasset, Inc.
Joseph Patti, Ph.D., Co-founder, CSO, Inhibitex, Inc.
Stuart Cockerill, Ph.D., Head of Discovery, Virology, Arrow Therapeutics/Astra Zeneca
Richard Colonno, Ph.D., Chief Scientific Officer, Presidio Pharmaceuticals
Juswinder Singh, Ph.D., CSO, Avila Therapeutics
Nigel Liverton, Ph.D., Distinguished Senior Investigator, External Discovery and Preclinical Sciences, Merck Research Laboratories
Wieslaw Kazmierski, Ph.D., Senior Chief Scientist, HCV Medicinal Chemistry, GlaxoSmithKline
Atul Agarwal, Ph.D., Senior Director, Computational Chemistry & Informatics, Achillion Pharmaceuticals, Inc.
Kenny Simmen, Ph.D., Vice President, Disease Strategy, Tibotec BVBA Pharmaceuticals, Inc.
A. Donny Strosberg, Ph.D., Professor, Department of Infectology, Scripps Research Institute-Florida
Jeffrey McKelvy, M.D., Ph.D., CEO, iTherX
James Appleman, M.D., Vice President Preclinical Biology and Translational Research, Anadys
Hengli Tang, Ph.D., Assistant Professor, Biological Science, Florida State University

Kinase Inhibitor Speakers:

Philip LoGrasso, Ph.D., Associate Professor; Senior Director, Molecular Therapeutics, The Scripps Research Institute
Roderick E. Hubbard, Ph.D., Professor, Research, Vernalis, Ltd. (tentative)
Kyung Lee, Ph.D., Senior Investigator, Metabolism, National Cancer Institute
John D. Scott, FRS, Edwin G. Krebs - Speights Professor of Cell Signaling and Cancer Biology, Howard Hughes Medical Institute, Department of Pharmacology, University of Washington School of Medicine Seattle
Karsten Niefind, Ph.D., Department of Chemistry, Institute of Biochemistry, University of Cologne
Jose Duca, Ph.D., Senior Principal Scientist, 3D-Drug Design Department, Merck Research Laboratories
Justin Dietrich, Ph.D., Department of Pharmacology and Toxicology, University of Arizona, College of Pharmacy
Li Xing, Ph.D., Senior Principal Scientist, Pfizer Global Research and Development, St. Louis Laboratories
Maria Argiriadi, Ph.D., Prinzipal Scientist, Molecular Pharmacology, Abbott Laboratories
David Berkowitz, Ph.D., Professor, Chemistry, University of Nebraska
Jordan Fridman, Ph.D., Director, Pharmacology, Incyte
Jacques Ermolieff, Ph.D., Senior Principal Scientist, Biochemical Pharmacology, Pfizer, La Jolla
Hui Li, Ph.D., Pfizer, Inc.
Juswinder Singh, Ph.D., CSO, Avila Therapeutics

Protein-Protein Interactions Speakers:

Michelle Arkin, Ph.D., Associate Director, Biology, Small Molecule Discovery Center, University of California, San Francisco
David C. Fry, Ph.D., Senior Research Leader, R&D Discovery Chemistry, Roche
Nicholas Cosford, Ph.D., Associate Professor, Apoptosis and Cell Death Signaling, Burnham Institute for Medical Research
Haian Fu, Ph.D., Professor, Pharmacology; Director, Emory Chemical Biology Discovery Center, Emory University School of Medicine
Alex Burgin, Chief Operating Officer, Emerald BioStructures
John Porter, Ph.D., Senior Principal Scientist, UCB Celltech
Valerica Raicu, Ph.D., Associate Professor, Physics; Biological Sciences, University of Wisconsin-Milwaukee
Xavier Morelli, Group Leader, Structural Biology, Centre National de la Recherche Scientifique (CNRS)
IMR Laboratory, CNRS-IMM
Pierfausto Seneci, Ph.D., Professor, Organic and Industrial Chemistry, CISI, University of Milan
Stefanie Reich, Ph.D., Senior Biologist, Department of Biology, Domainex, Ltd.
Lars-Gunnar Larsson, Professor, Microbiology, Tumor and Cell Biology, Karolinska Institute
Seetharama Satyanarayanajois, Assistant Professor, Medicinal Chemistry, Basic Pharmaceutical Sciences, University of Louisiana at Monroe
Jolanta Grembecka, Assistant Professor, Pathology, University of Michigan
Jody Mason, Lecturer, Biological Sciences, University of Essex
Bill Harten, CEO, CTO, UNIConnect
Sandor Vajda, Ph.D., Professor, Biomedical Engineering, Boston University
John O'Bryan, Assistant Professor, Pharmacology, University of Illinois College of Medicine